OPKO Health operates through two primary business segments: Diagnostics and Pharmaceuticals. The Diagnostics segment is anchored by BioReference Laboratories, one of the largest clinical laboratories in the United States, offering routine testing, molecular diagnostics, anatomical pathology, and the proprietary 4Kscore test for prostate cancer. The Pharmaceuticals segment features commercialized products such as Rayaldee for secondary hyperparathyroidism and NGENLA, a human growth hormone partnered with Pfizer. Additionally, through its ModeX Therapeutics subsidiary, OPKO is advancing a clinical pipeline of multispecific antibodies and vaccines targeting oncology and infectious diseases. The company maintains a global footprint with pharmaceutical operations, research facilities, and commercial partnerships across the United States, Europe, Latin America, and Israel.
